203 related articles for article (PubMed ID: 30068618)
1. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.
Collin LJ; Cronin-Fenton DP; Ahern TP; Christiansen PM; Damkier P; Ejlertsen B; Hamilton-Dutoit S; Kjærsgaard A; Silliman RA; Sørensen HT; Lash TL
BMJ Open; 2018 Aug; 8(7):e021805. PubMed ID: 30068618
[TBL] [Abstract][Full Text] [Related]
2. Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study.
Cronin-Fenton DP; Kjærsgaard A; Ahern TP; Mele M; Ewertz M; Hamilton-Dutoit S; Christiansen PM; Ejlertsen B; Sørensen HT; Lash TL; Silliman RA
Acta Oncol; 2017 Sep; 56(9):1155-1160. PubMed ID: 28585885
[TBL] [Abstract][Full Text] [Related]
3. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
4. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
[TBL] [Abstract][Full Text] [Related]
5. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients.
Ahern TP; Collin LJ; Baurley JW; Kjærsgaard A; Nash R; Maliniak ML; Damkier P; Zwick ME; Isett RB; Christiansen PM; Ejlertsen B; Lauridsen KL; Christensen KB; Silliman RA; Sørensen HT; Tramm T; Hamilton-Dutoit S; Lash TL; Cronin-Fenton D
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):582-590. PubMed ID: 31932415
[TBL] [Abstract][Full Text] [Related]
7. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study.
Collin LJ; Maliniak ML; Cronin-Fenton DP; Ahern TP; Christensen KB; Ulrichsen SP; Damkier P; Hamilton-Dutoit S; Yacoub R; Christiansen PM; Sørensen HT; Lash TL
Breast Cancer Res; 2021 Nov; 23(1):103. PubMed ID: 34736510
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study.
Cronin-Fenton DP; Hellberg Y; Lauridsen KL; Ahern TP; Garne JP; Rosenberg C; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
Acta Oncol; 2012 Feb; 51(2):254-61. PubMed ID: 22129357
[TBL] [Abstract][Full Text] [Related]
11. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer.
Sugimachi K; Maehara Y; Akazawa K; Nomura Y; Eida K; Ogawa M; Konaga E; Tanaka N; Toge T; Dohi K; Noda S; Maeda M; Monden Y
Breast Cancer Res Treat; 1999 Jul; 56(2):113-24. PubMed ID: 10573104
[TBL] [Abstract][Full Text] [Related]
12. Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer.
Borner MM; Bacchi M; Castiglione M
Eur J Cancer; 1996 Nov; 32A(12):2173-6. PubMed ID: 9014762
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.
Andersson M; Kamby C; Jensen MB; Mouridsen H; Ejlertsen B; Dombernowsky P; Rose C; Cold S; Overgaard M; Andersen J; Kjaer M
Eur J Cancer; 1999 Nov; 35(12):1659-66. PubMed ID: 10674010
[TBL] [Abstract][Full Text] [Related]
14. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
15. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
[TBL] [Abstract][Full Text] [Related]
16. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
Nomura Y; Shirouzu M; Takayama T
Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
[TBL] [Abstract][Full Text] [Related]
17. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
[TBL] [Abstract][Full Text] [Related]
18. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark.
Hjorth CF; Damkier P; Ejlertsen B; Lash T; Sørensen HT; Cronin-Fenton D
BMC Med; 2021 Sep; 19(1):235. PubMed ID: 34587961
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
